Back to Search Start Over

Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening.

Authors :
Jenquin JR
O'Brien AP
Poukalov K
Lu Y
Frias JA
Shorrock HK
Richardson JI
Mazdiyasni H
Yang H
Huigens RW 3rd
Boykin D
Ranum LPW
Cleary JD
Wang ET
Berglund JA
Source :
IScience [iScience] 2022 Apr 04; Vol. 25 (5), pp. 104198. Date of Electronic Publication: 2022 Apr 04 (Print Publication: 2022).
Publication Year :
2022

Abstract

Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are common forms of adult onset muscular dystrophy. Pathogenesis in both diseases is largely driven by production of toxic-expanded repeat RNAs that sequester MBNL RNA-binding proteins, causing mis-splicing. Given this shared pathogenesis, we hypothesized that diamidines, small molecules that rescue mis-splicing in DM1 models, could also rescue mis-splicing in DM2 models. While several DM1 cell models exist, few are available for DM2 limiting research and therapeutic development. Here, we characterize DM1 and DM2 patient-derived fibroblasts for use in small molecule screens and therapeutic studies. We identify mis-splicing events unique to DM2 fibroblasts and common events shared with DM1 fibroblasts. We show that diamidines can partially rescue molecular phenotypes in both DM1 and DM2 fibroblasts. This study demonstrates the potential of fibroblasts as models for DM1 and DM2, which will help meet an important need for well-characterized DM2 cell models.<br />Competing Interests: The authors declare no competing interests.<br /> (© 2022 The Author(s).)

Details

Language :
English
ISSN :
2589-0042
Volume :
25
Issue :
5
Database :
MEDLINE
Journal :
IScience
Publication Type :
Academic Journal
Accession number :
35479399
Full Text :
https://doi.org/10.1016/j.isci.2022.104198